ZBIO Zenas BioPharma, Inc.
Debt Financing ·
Zenas BioPharma closed a $200 million offering of 2.50% convertible senior notes due 2032, with net proceeds of about $193.7 million and Jefferies, Evercore, Citigroup and Guggenheim as representatives. Its 10-K reports substantial doubt about going concern.
Zenas gains global rights to the BTK inhibitor outside oncology plus two early autoimmune drugs. It also registered an at-the-market program for up to $200,000,000 of stock with Jefferies.
Zenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.
Royalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.0 million | $5.0 million |
| Research and development | $168.1 million | $139.1 million |
| Net income (loss) | -$377.7 million | -$157.0 million |
| Cash from operations | -$172.3 million | -$119.7 million |
| Cash and equivalents | $110.6 million | $319.7 million |
| Short-term investments | $232.6 million | $31.0 million |
Our latest story on this, dated Mar 31, 2026: "Zenas BioPharma closes $200,000,000 convertible senior notes offering due 2032". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2026: "Zenas BioPharma closes $200,000,000 convertible senior notes offering due 2032". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2026: "Zenas BioPharma closes $200,000,000 convertible senior notes offering due 2032". The story links the filing or release it is based on. Read the story.
Zenas BioPharma, Inc. trades under the ticker ZBIO on NASDAQ.
Zenas BioPharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Zenas BioPharma, Inc. is 1953926. Its filings are on SEC EDGAR.
65,176,723 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Zenas BioPharma, Inc. under United States.
Our directory classifies Zenas BioPharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Zenas BioPharma, Inc. is US98937L1052.
aibio.space lists Zenas BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$10.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Zenas BioPharma, Inc. reported a net loss of $377.7 million for the fiscal year ended Dec 31, 2025, and used $172.3 million of cash in operations, per its annual report to the SEC.
$168.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio